Anti-Human PCSK9 (Evolocumab Biosimilar)
Catalog #500028
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500028 | 1 mg | $200.00 | ||
| 500028 | 5 mg | $600.00 | ||
| 500028 | 20 mg | $1,250.00 |
Product Details
Anti-PCSK9 (Evolocumab Biosimilar) is a high-affinity human IgG2 monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). It effectively blocks PCSK9 from binding to low-density lipoprotein receptors (LDLRs), thereby preventing receptor degradation and promoting LDL cholesterol clearance. This biosimilar to Evolocumab is widely used in cardiovascular and lipid metabolism research.
Specifications
| Clone | Evolocumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG2 |
| Recommended Isotype Control | Human IgG2 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human PCSK9 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |